Antonio Lee | Chief Executive Officer & Managing Director
MEDIPOST America | Republic Of Korea

Antonio Lee, Chief Executive Officer & Managing Director, MEDIPOST America

Dr. Antonio Lee is the Global Head of Business Development at MEDIPOST (KOSDAQ: 078160; Seoul, Korea) and also serves as the CEO and Managing Director at MEDIPOST America Inc., a wholly-owned U.S. subsidiary of MEDIPOST.

Since 2011, Dr. Lee has been involved in the global commercialization and clinical development strategy, regulatory affairs and marketing of human Umbilical Cord Blood (hUCB)-derived Stem Cell technology and products developed by MEDIPOST, including the World’s First regulatory-approved allogeneic stem cell product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA).

Dr. Lee also serves as the Chair of the Board of Directors for MEDIPOST’s North Asian Joint-Venture entities – ‘Shandong ORLIFE Pharmaceuticals, Shandong, China’ and ‘EVASTEM Therapeutics, Tokyo, Japan’.

Prior to joining MEDIPOST, Dr. Lee held research scientist positions in the field of Stem Cell Biology & Regenerative Medicine at the University of Sydney and the University of New South Wales, Sydney, Australia and received his Ph.D. in Developmental and Stem Cell Biology from the University of Otago, New Zealand.

Appearances:



Phar-East Day 1 @ 12:20

Development of cell therapy product for pediatric orphan disease - challenges and rewards

  • Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)
  • Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what’s next beyond Asia?
last published: 26/Sep/18 02:35 GMT

back to speakers

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738